Arcus Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript
Good morning, everyone. Thank you so much for joining us for the presentation with Arcus. We're really pleased to have Terry Rosen, CEO; and Jennifer Jarrett, COO. With that, Terry, I'm going to turn it over to you. Just given you've got a ton of data reads this year, maybe you could just put it in context and then we can jump in.
Sure. Thanks, Salveen. So Arcus has been around since 2015. And I think big difference between how we ended 2021 and how we'll end 2022 and maybe I'll level set where we are in that context. So as we ended 2021, we had one registrational trial. And as everybody knows, we have 6 molecules in the clinic: 2 in the ATP adenosine pathway, 2 anti-TIGIT, our anti-PD-1 and our most recent, our HIF-2 inhibitor, AB521.
With the data that we generated in ARC-7 in our third interim analysis, that totally reinforced our plans for registrational studies around the anti-TIGIT/zimberelimab
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |